Behavior of metastatic breast cancer according to subtype.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ therapeutic use
Bone Neoplasms
/ secondary
Breast Neoplasms
/ classification
Combined Modality Therapy
Cross-Sectional Studies
Female
Follow-Up Studies
Humans
Liver Neoplasms
/ secondary
Mastectomy
/ mortality
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
Trastuzumab
/ therapeutic use
Breast cancer subtype
Disease free survival
Disease specific survival
Metastatic breast cancer
Trastuzumab
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
23
10
2019
accepted:
12
03
2020
pubmed:
21
3
2020
medline:
9
1
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
To explore the impact of breast cancer subtype on metastatic behavior and long-term outcome defined as breast cancer specific survival (BCSS). Retrospective single centre cross-sectional study of 5972 patients with newly diagnosed, unilateral first diagnosis of breast cancer, diagnosed 2000-2010. Patients had either early breast cancer (EBC) treated primarily by surgery (SURG n = 5072), neoadjuvant systemic therapy (NEO n = 592), or upfront metastatic disease (META n = 308). Surrogate breast cancer subtypes were defined according to classical pathological criteria. Analysis was performed using Kaplan-Meier method and logistic/Cox regression. After median follow-up time of 103.6 months (IQR 73.4-139.2 months), 817 patients with EBC at diagnosis (14.4%) developed distant metastases of which 621 (12.2%) SURG and 196 (33.1%) NEO. Metastasis rate after EBC was: LuminalA 8.1%, LuminalB1(HER2-) 20.4%, LuminalB2(HER2+) without (neo)adjuvant trastuzumab 21.7%, LuminalB2(HER2+) with trastuzumab 9.0%, HER2Positive(ER-) without trastuzumab 30.0%, HER2Positive(ER-) with trastuzumab 19.9% and TripleNegative 25.3%. There were major differences in site of first metastases according to subtype. For single site first metastases, median BCSS assessed from time of metastases was worst for brain localization (13.9 months) and best for bone (48.4 months). Multiple sites of first metastases had worse BCSS from date of metastases than single site first metastases (median BCSS for 1 site 40.0, 2 sites 27.1, ≥ 3 sites 20.5 months). Median BCSS from date of metastases is longer in upfront metastases compared to secondary metastases after EBC (43.4 vs. 27.9 months). Tumor subtype influences the metastatic behavior and survival after development of distant metastases.
Identifiants
pubmed: 32193802
doi: 10.1007/s10549-020-05597-3
pii: 10.1007/s10549-020-05597-3
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-125Commentaires et corrections
Type : ErratumIn
Références
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, Committee EG (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–30. https://doi.org/10.1093/annonc/mdv298
doi: 10.1093/annonc/mdv298
pubmed: 26314782
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546. https://doi.org/10.1093/annonc/mdv221
doi: 10.1093/annonc/mdv221
pubmed: 25939896
pmcid: 4511219
Brouckaert O, Schoneveld A, Truyers C, Kellen E, Van Ongeval C, Vergote I, Moerman P, Floris G, Wildiers H, Christiaens MR, Van Limbergen E, Neven P, Mbc Leuven B (2013) Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. Ann Oncol 24(7):1847–1852. https://doi.org/10.1093/annonc/mdt179
doi: 10.1093/annonc/mdt179
pubmed: 23680691
Bartmann C, Wischnewsky M, Stuber T, Stein R, Krockenberger M, Hausler S, Janni W, Kreienberg R, Blettner M, Schwentner L, Wockel A, Diessner J (2017) Pattern of metastatic spread and subcategories of breast cancer. Arch Gynecol Obstet 295(1):211–223. https://doi.org/10.1007/s00404-016-4225-4
doi: 10.1007/s00404-016-4225-4
pubmed: 27832352
Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, Jager D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schutz F, Sohn C, Heil J, Schneeweiss A (2016) Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 16(1):734. https://doi.org/10.1186/s12885-016-2766-3
doi: 10.1186/s12885-016-2766-3
pubmed: 27634735
pmcid: 5024419
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304
doi: 10.1093/annonc/mdr304
pubmed: 3144634
pmcid: 3144634
Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P (2015) Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat 150(3):621–629. https://doi.org/10.1007/s10549-015-3341-3
doi: 10.1007/s10549-015-3341-3
pubmed: 25783184
Ording AG, Heide-Jorgensen U, Christiansen CF, Norgaard M, Acquavella J, Sorensen HT (2017) Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastasis 34(1):93–101. https://doi.org/10.1007/s10585-016-9824-8
doi: 10.1007/s10585-016-9824-8
pubmed: 27718076